Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36161479.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2427.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tilsotolimod, an oligodeoxynucleotide TLR9 agonist, administered intratumorally, has been clinically evaluated. This compound has demonstrated the ability to induce changes within the tumor microenvironment, to convert noninflamed cold tumors into inflamed hot tumors, with the hope that these tumors will be more responsive to immune checkpoint blockade. See related article by Babiker et al., p. 5079.
Medical subject headings
- Toll-Like Receptor 9
- Neoplasms